Trial Profile
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary) ; Corticosteroids; Itraconazole
- Indications Cystic fibrosis-associated respiratory tract infections; Invasive bronchopulmonary aspergillosis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 May 2016 This trial was completed in Belgium according to the European Clinical Trials Database.
- 03 Apr 2012 New trial record